Publications by authors named "Matthias von Herrath"

230 Publications

Current and future therapies for type 1 diabetes.

Diabetologia 2021 Feb 17. Epub 2021 Feb 17.

Global Chief Medical Office, Novo Nordisk A/S, Søborg, Denmark.

View Article and Find Full Text PDF
February 2021

New Insights Into the Role of Autoreactive CD8 T Cells and Cytokines in Human Type 1 Diabetes.

Front Endocrinol (Lausanne) 2020 5;11:606434. Epub 2021 Jan 5.

Center for Autoimmunity and Inflammation, Type 1 Diabetes Center at La Jolla Institute for Immunology, La Jolla, CA, United States.

View Article and Find Full Text PDF
January 2021

The healthy exocrine pancreas contains preproinsulin-specific CD8 T cells that attack islets in type 1 diabetes.

Sci Adv 2020 Oct 16;6(42). Epub 2020 Oct 16.

Center for Type 1 Diabetes Research, La Jolla Institute for Immunology, La Jolla, CA, USA.

View Article and Find Full Text PDF
October 2020

Interference with pancreatic sympathetic signaling halts the onset of diabetes in mice.

Sci Adv 2020 Aug 26;6(35). Epub 2020 Aug 26.

La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

View Article and Find Full Text PDF
August 2020

Long-term viability through selective permeability.

Nat Biomed Eng 2020 08;4(8):763-764

Chief Medical Office, Novo Nordisk A/S, Søborg, Denmark.

View Article and Find Full Text PDF
August 2020

IL-4R is expressed on alpha and beta cells of human pancreata.

Clin Immunol 2020 05 26;214:108394. Epub 2020 Mar 26.

La Jolla Institute for Immunology, La Jolla, CA, United States of America. Electronic address:

View Article and Find Full Text PDF
May 2020

Human herpesvirus-6 is present at higher levels in the pancreatic tissues of donors with type 1 diabetes.

J Autoimmun 2020 02 6;107:102378. Epub 2019 Dec 6.

Type 1 Diabetes Center, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA. Electronic address:

View Article and Find Full Text PDF
February 2020

CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor.

Diabetologia 2019 09 17;62(9):1727-1729. Epub 2019 May 17.

Novo Nordisk A/S Research Projects, Novo Nordisk Park, DK-2760, Måløv, Denmark.

View Article and Find Full Text PDF
September 2019

Regulatory Immune Mechanisms beyond Regulatory T Cells.

Trends Immunol 2019 06 14;40(6):482-491. Epub 2019 May 14.

Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA; Novo Nordisk Research Center, Seattle, WA, USA. Electronic address:

View Article and Find Full Text PDF
June 2019

The Development of Immunotherapy Strategies for the Treatment of Type 1 Diabetes.

Front Med (Lausanne) 2018 9;5:283. Epub 2018 Oct 9.

Novo Nordisk (Denmark), Copenhagen, Denmark.

View Article and Find Full Text PDF
October 2018

Distinct Housing Conditions Reveal a Major Impact of Adaptive Immunity on the Course of Obesity-Induced Type 2 Diabetes.

Front Immunol 2018 28;9:1069. Epub 2018 May 28.

Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.

View Article and Find Full Text PDF
July 2019

Oral insulin does not alter gut microbiota composition of NOD mice.

Diabetes Metab Res Rev 2018 09 1;34(6):e3010. Epub 2018 May 1.

Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.

View Article and Find Full Text PDF
September 2018

OAS1 is not associated with MHC class I hyperexpression in the islets of donors with T1D regardless of disease duration.

Clin Immunol 2018 06 15;191:34-36. Epub 2018 Mar 15.

Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92037, USA; Novo Nordisk Diabetes Research & Development Center, Seattle, Washington, USA. Electronic address:

View Article and Find Full Text PDF
June 2018

α Cell Function and Gene Expression Are Compromised in Type 1 Diabetes.

Cell Rep 2018 03;22(10):2667-2676

Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA; Department of Veterans Affairs, Tennessee Valley Healthcare System, Nashville, TN, USA. Electronic address:

View Article and Find Full Text PDF
March 2018

The shifting paradigm of a "cure" for type 1 diabetes: is technology replacing immune-based therapies?

Acta Diabetol 2018 Feb 29;55(2):117-120. Epub 2017 Nov 29.

Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA, USA.

View Article and Find Full Text PDF
February 2018

Antigen-Specific Peptide Immunotherapy for Type 1 Diabetes: Proof of Safety, Hope for Efficacy.

Cell Metab 2017 Oct;26(4):595-597

Type 1 Diabetes Research Center, Novo Nordisk, Seattle, WA, USA; Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, La Jolla, CA 92014, USA. Electronic address:

View Article and Find Full Text PDF
October 2017

β-Cell mass versus function in type 1 diabetes mellitus: truth or dare?

Nat Rev Endocrinol 2017 09 7;13(9). Epub 2017 Jul 7.

Type 1 Diabetes Center, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, California 92037, USA; and at the Novo Nordisk Diabetes Research &Development Center, 530 Fairview Ave N # 5000, Seattle, Washington 98109, USA.

View Article and Find Full Text PDF
September 2017